MARKET

LGND

LGND

Ligand Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

123.63
+2.80
+2.32%
After Hours: 123.63 0 0.00% 17:01 06/11 EDT
OPEN
121.49
PREV CLOSE
120.83
HIGH
123.91
LOW
120.09
VOLUME
112.20K
TURNOVER
--
52 WEEK HIGH
219.75
52 WEEK LOW
78.26
MARKET CAP
2.06B
P/E (TTM)
53.42
1D
5D
1M
3M
1Y
5Y
Ligand (LGND) Down 14% Since Last Earnings Report: Can It Rebound?
Zacks.com · 06/02 15:30
BRIEF-Genscript Biotech And Ligand Pharmaceuticals Enter Into Global Omniab Licensing Agreement
reuters.com · 06/02 13:03
GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement
, and SAN , /PRNewswire/ -- GenScript Biotech Corporation (HKG: 1548) along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that they have entered into a strategic licensing agreement for Liga...
PR Newswire - PRF · 06/02 13:00
Ligand Pharmaceuticals, GenScript Biotech Sign Licensing Agreement for Antibody Discovery
MT Newswires · 06/02 09:50
We Think Some Shareholders May Hesitate To Increase Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) CEO Compensation
In the past three years, the share price of Ligand Pharmaceuticals Incorporated ( NASDAQ:LGND ) has struggled to grow...
Simply Wall St. · 05/29 09:01
FDA grants J&J multiple myeloma treatment cilta-cel priority review
The FDA has accepted with priority review the BLA for Johnson & Johnson (JNJ) Janssen unit's ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma.The PDUFA date is November 29, 2021.Janssen began a
Seekingalpha · 05/26 21:41
Investment Management Of Virginia Llc Buys Medtronic PLC, CollPlant Biotechnologies, Quidel ...
GuruFocus News · 05/20 15:38
Heres Why Ligand Pharmaceuticals (LGND) Became Wasatch Globals Q1 2021 Top Contributor
Wasatch Global Investors, an investment management firm, published its “Wasatch Core Growth Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 5.59% was recorded by the fund for the Q1 of 2021, trailing the bench...
Insider Monkey · 05/10 18:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LGND. Analyze the recent business situations of Ligand Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LGND stock price target is 213.57 with a high estimate of 310.00 and a low estimate of 180.00.
EPS
Institutional Holdings
Institutions: 409
Institutional Holdings: 19.18M
% Owned: 115.21%
Shares Outstanding: 16.65M
TypeInstitutionsShares
Increased
56
867.89K
New
36
87.60K
Decreased
103
6.14M
Sold Out
46
2.17M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.29%
Pharmaceuticals & Medical Research
-0.72%
Key Executives
Non-Executive Chairman/Independent Director
John Kozarich
President/Chief Operating Officer
Matthew Foehr
Chief Executive Officer/Director
John Higgins
Chief Financial Officer/Executive Vice President - Finance
Matthew Korenberg
Senior Vice President/General Counsel/Secretary
Charles Berkman
Independent Director
Jason Aryeh
Independent Director
Sarah Boyce
Independent Director
Todd Davis
Independent Director
Nancy Gray
Independent Director
John LaMattina
Independent Director
John Lamattina
Independent Director
Sunil Patel
Independent Director
Stephen Sabba
Declaration Date
Dividend Per Share
Ex-Div Date
03/20/2007
Dividend USD 2.5
04/03/2007
About LGND
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.

Webull offers kinds of Ligand Pharmaceuticals Inc. stock information, including NASDAQ:LGND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LGND stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LGND stock methods without spending real money on the virtual paper trading platform.